Literature DB >> 2887738

Cost-benefit analysis of hepatitis-B vaccination.

D Lahaye, P Strauss, C Baleux, W van Ganse.   

Abstract

Since 1983 the Belgian insurance Fund for Occupational Disease (FOD) has refunded the cost of hepatitis-B (HB) vaccination. Vaccination has been carried out by occupational physicians selectively on staff in hospitals and medical-care institutions. At the end of 1986, 40,000 people at high risk of HBV infection had been vaccinated. The vaccination costs are largely offset by the benefits resulting from the striking fall in the number of HB cases. The financial investment has proved economically beneficial for the insurance fund.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887738     DOI: 10.1016/s0140-6736(87)90971-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; D Shouval
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

Review 2.  Pharmacoeconomics of immunisation: a review.

Authors:  R van den Oever; D de Graeve; B Hepp; A Stroobant; D Walckiers; V Van Casteren; F Van Loock; G Ducoffre; J Dewatripont; P Jacques
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

3.  Therapeutic conservatism: more costly in the long term? A UK perspective.

Authors:  J P Griffin
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 4.  Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).

Authors:  Giuseppe La Torre; Alice Mannocci; Rosella Saulle; Vittoria Colamesta; Angela Meggiolaro; Daniele Mipatrini; Alessandra Sinopoli
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

Review 5.  Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.

Authors:  S M Holliday; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

Review 6.  Hepatitis B and hepatitis delta virus infection in South America.

Authors:  J R Torres
Journal:  Gut       Date:  1996       Impact factor: 23.059

7.  The economic burden of hepatitis B in Germany.

Authors:  S Harbarth; T Szucs; K Berger; W Jilg
Journal:  Eur J Epidemiol       Date:  2000-02       Impact factor: 8.082

8.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; S Berger; D Shouval
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

9.  The estimation of direct medical costs of treating patients with chronic hepatitis B and C in iran.

Authors:  Hamid Kalantari; Majid Davari; Mojtaba Akbari; Seyed Mehdi Hejazi; Maryam Kalantari; Shahram Zakerin; Zahra Shahshahan
Journal:  Int J Prev Med       Date:  2012-03

10.  Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil.

Authors:  Lia L Lewis-Ximenez; Kycia M R do O; Cleber F Ginuino; Jucimara C Silva; Hermann G Schatzmayr; Sherri Stuver; Clara F T Yoshida
Journal:  BMC Public Health       Date:  2002-11-22       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.